Loss of Expression of Cyclin D2 by Aberrant DNA Methylation: a Potential Biomarker in Vietnamese Breast Cancer Patients |
Truong, Phuong Kim
(Molecular, Biotechnology, Ho Chi Minh City Open University)
Lao, Thuan Duc (Molecular, Biotechnology, Ho Chi Minh City Open University) Doan, Thao Phuong Thi (Department of Pathological Anatomy, Faculty of Medicine, Ho Chi Minh City Medicine and Pharmacy University) Huyen Le, Thuy Ai (Molecular, Biotechnology, Ho Chi Minh City Open University) |
1 | Virmani A, Rathi A, Heda S, et al (2003). Aberrant methylation of the cyclin D2 promoter in primary small cell, non-small cell lung and breast cancers. Int J Cancer, 107, 341-5. DOI |
2 | Yu J, Leung WK, Ebert MP, et al (2003). Absence of cyclin D2 expression is associated with promoter hypermethylation in gastric cancer. Br J Cancer, 88, 1560-5. DOI |
3 | Zhang P (1999). The cell cycle and development: redundant roles of cell cycle regulators. Curr Opin Cell Biol, 11, 655-62 DOI |
4 | Zhu WG, Dai Z, Ding H, et al (2001). Increased expression of unmethylated CDKN2D by 5-aza-2'-deoxycytidine in human lung cancer cells. Oncogene, 20, 7787-96. DOI |
5 | Anna Hsu, Carmen P Wong, Zhen Yu, et al (2011) Promoter de-methylation of cyclin D2 by sulforaphane in prostate cancer cells. Clin Epigenetics, 3, 3. DOI |
6 | Chomczynski P, Sacchi N (1987). Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem, 162, 156-9. |
7 | Padar A, Sathyanarayana UG, Suzuki M, et al (2003). Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation. Clin Cancer Res, 9, 4730-4. |
8 | Evron E, Umbricht CB, Korz D, et al (2001). Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. Cancer Res, 61, 2782-7. |
9 | Fackler MJ, McVeigh M, Evron E, et al (2003). DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. Int J Cancer, 107, 970-5. DOI |
10 | Li S, Rong M, Iacopetta B (2006). DNA hypermethylation in breast cancer and its association with clinicopathological features. Cancer Lett, 237, 272-80. DOI |
11 | Pongtheerat T, Pakdeethai S, Purisa W, Chariyalertsak S, Petmitr S (2011). Promoter methylation and genetic polymorphism of glutathione S-transferase P1 gene (GSTP1) in Thai breast- cancer patients. Asian Pac J Cancer Prev, 12, 2731-4. |
12 | Prowell TM, Fackler M, Argani P, et al (2008). A prospective study of adjuvant anastrozole and gene promoter methylation in the contralateral breast of high-risk women. J Clin Oncol, 26, 1514. |
13 | Ramezani F, Salami S, Omrani MD, Maleki D (2012). CpG island methylation profile of estrogen receptor alpha in Iranian females with triple negative or non-triple negative breast cancer: new marker of poor prognosis. Asian Pac J Cancer Prev, 13, 451-7. DOI ScienceOn |
14 | Truong PK, Lao TD, Doan TPT, Le TAH (2014). BRCA1 promoter hypermethylation signature for early detection of breast cancer in the Vietnamese population. Asian Pac J Cancer Prev, 15, 9601-10. |
15 | Uhm TG, Lee SK, Kim BS, et al (2012). CpG methylation at GATA elements in the regulatory region of CCR3 positively correlates with CCR3 transcription. Exp Mol Med, 44, 268-80 DOI |